Best Practices for Implementing NGS and Positioning for Future Growth

Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and community based cancer medical center – provided their perspectives on how they approach the challenge of addressing this need. The speakers will present on the reasons why they chose to internalize NGS testing, the value it brings to their healthcare system/network and what was involved to actualize their programs. Digital analytics and analysis employed by LTS Health was incorporated to provide feedback on the impact to laboratory operations and forecasting for future growth.  

Keith Gligorich, PhD, is the Laboratory Operations Director at NAVICAN Precision Cancer Care, an Intermountain Healthcare Company. NAVICAN provides TheraMap™, an end-to-end solution helping oncologists and patients harness the power of precision genomics, clinical analytics, and patient services for optimal cancer management. Prior to joining NAVICAN, Dr. Gligorich was a Research Assistant Professor in the Department of Pathology at the University of Utah and a Lead Scientist at ARUP Laboratories. In this role, he led a team of scientists focused on developing solid tumor molecular and NGS diagnostic tests. Dr. Gligorich earned a PhD in Chemistry from the University of Utah. He continued his training as a Department of Defense Breast Cancer Research Program Post-Doctoral Fellow at the Huntsman Cancer Institute.